Published in:
01-06-2015 | PHASE I STUDIES
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience
Authors:
Akihito Kawazoe, Kohei Shitara, Shota Fukuoka, Masaaki Noguchi, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Toshihiko Doi
Published in:
Investigational New Drugs
|
Issue 3/2015
Login to get access
Summary
Background Although patients with advanced gastric cancer (AGC) have a poor prognosis when conventional therapies fail, they are often candidates for phase I trials. However, there is no detailed report on clinical outcomes of patients with AGC treated in phase I trials. Methods We retrospectively reviewed the medical records of 66 consecutive patients with AGC enrolled in phase I trials between March 2008 and July 2014 at our institution in Japan. Results Median age was 66 years (range, 28–78 years) and median number of previous lines of conventional chemotherapy was 3 (range, 1–6). Five (8.6 %) and seven (12 %) patients showed objective response and stable disease >3 months, respectively. Although the time to treatment failure (TTF) of the best phase I treatment was shorter than that of the last line of conventional chemotherapy (median 1.5 vs. 2.3 months; P = 0.002), TTF of the best phase I treatment was longer than that of the last line of treatment in 21 patients (32 %). Severe adverse events and grade 3 or higher toxicities were reported in eight (12 %) and 13 patients (20 %), respectively. No treatment-related death was observed. Median survival time from the start of phase I treatment was 7.5 months, and four deaths (6 %) within 30 days after last administration were observed. Conclusion Phase I trials of patients with AGC was acceptably feasible with some efficacy signal. Our results suggest that phase I trials might be one treatment option for patients with AGC when conventional therapies fail.